Shire is giving serious consideration on unloading Dermagraft!
Ornskov also said that divesting Dermagraft, a treatment for diabetic foot ulcers, isn’t out of the question, this person said. Shire acquired the product with its $750 million purchase of Advanced Biohealing Inc. in May 2011. The company abandoned efforts to develop Dermagraft for leg ulcers in August 2011 after it failed in a clinical trial. Sales of Dermagraft dropped 65 percent to $19 million in the fourth quarter, Shire said Feb. 14.
Before that, Smith & Nephew abandoned Dermagraft and sold the product to Advanced Biohealing after a failed leg ulcer trial. I'll see if I can re-dig up "why" it have failed in the Smith & Nephew days.
Looks like yahoo may have deleted my post for pasting a study. The studies on foot ulcers tend to be of the neuropathic variety. One of the treatment regimens for diabetic foot ulcers is patient offloading.
The Dermagraft studies looked at leg ulcers of the venous insufficiency variety which typically requires pressure to aid in proper circulation. Many physicians utilize Negative wound pressure to prep the patient for grafting.